Mycoplasma gallisepticum culture medium and preparation method thereof
By optimizing the composition and preparation method of Mycoplasma gallisepticum culture medium, the problem of low titer of Mycoplasma gallisepticum culture was solved, and efficient vaccine production was achieved.
Patent Information
- Application Number
- CN202411119872.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing culture media have poor proliferation capacity and low culture titers when culturing Mycoplasma gallisepticum, resulting in weak vaccine protective efficacy and high production costs.
A culture medium containing specific proportions and types of amino acids, trace elements, and nutrients for Mycoplasma gallisepticum was used, combined with suitable pH and sterilization conditions, to optimize the growth environment of Mycoplasma gallisepticum.
It significantly improved the culture titer of Mycoplasma chickenis, shortened the passage time, reduced production costs, and simplified the vaccine preparation process.
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of veterinary biology, and in particular to a Mycoplasma gallisepticum culture medium and a preparation method thereof. Background Art
[0002] Mycoplasma Galliscepticum (MG) infection is a type of respiratory disease in chickens, which mainly causes chronic respiratory disease (CRD), air sacitis and sinusitis. It is a pathogen that seriously endangers poultry production.
[0003] The infection characteristics of Mycoplasma gallisepticum are mainly colonization on the cilia and air sacs of the tracheal mucosa. There are no blood vessels at the ends of the tracheal cilia and on the air sacs. The drug is transported through the blood to the site of action and then acts on Mycoplasma gallisepticum through diffusion. Therefore, the drug can only reduce the number of Mycoplasma colonized on the tracheal cilia and air sacs and alleviate clinical symptoms, but cannot completely kill them. Therefore, Mycoplasma gallisepticum infection is generally a one-time infection that will cause a lifelong state of persistent infection. When the chickens are under stress, such as cold stimulation or vaccine immunization, clinical symptoms will appear again.
[0004] The main hazard of Mycoplasma gallisepticum is that the disease often spreads slowly in large-scale chicken farms, resulting in a decrease in the production of laying hens, stunted development of broilers and growing chickens, and reduced feed conversion rates; due to the immunosuppression of infected chickens, other diseases may occur secondary or concomitantly, and the main loss to the poultry industry is a significant increase in the mortality rate of infected chickens. The combined use of Mycoplasma gallisepticum live vaccine and inactivated vaccine can reduce the horizontal and vertical transmission of Mycoplasma gallisepticum, but the premise of high-quality vaccine is a good culture medium to support it.
[0005] Culture medium is a matrix of artificially synthesized nutrients for the growth of microorganisms. At present, the culture of Mycoplasma gallisepticum mainly uses modified Frey's or other mycoplasma culture medium. However, Mycoplasma gallisepticum cultured by traditional culture medium and culture process has poor proliferation ability and low culture titer (low culture solution concentration), which will lead to weak protective efficacy of the vaccine when preparing the finished vaccine, and the cost of vaccine production is relatively increased.
[0006] Therefore, how to provide a Mycoplasma gallisepticum culture medium to solve the problems existing in the above-mentioned prior art is a problem that those skilled in the art urgently need to solve. Summary of the invention
[0007] The object of the present invention is to provide a Mycoplasma gallisepticum culture medium and a preparation method thereof.
[0008] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0009] The invention provides a mycoplasma gallisepticum culture medium. The culture medium comprises the following components per liter: 15-20 g yeast extract, 4-6 g egg yolk phospholipids, 2-3 g L-cysteine, 1.2-1.8 g L-arginine hydrochloride, 1-2 g L-phenylalanine, 1-2 g L-alanine, 1-2 g L-lysine, 0.2-0.6 g methionine, 1-2 g L-tryptophan, 1-2 g L-proline, 2-4 g zinc sulfate, 2-4 g mannitol, 2-3 g trehalose, 2-4 g glutathione, 4-6 g malt extract, 2-3 g peptone, 5-7 mL fetal bovine serum, 4-6 g galactose, 0.2-0.4 g potassium dihydrogen phosphate and 2.2-2.8 g sodium pyruvate.
[0010] Preferably, the pH value of the culture medium is 7.5-7.7.
[0011] Preferably, the solvent of the culture medium is water.
[0012] The present invention also provides a method for preparing the Mycoplasma gallisepticum culture medium, comprising the following steps:
[0013] (1) mixing the components except fetal bovine serum with water and sterilizing to obtain material 1;
[0014] (2) After mixing the material 1 with fetal bovine serum, the pH is adjusted.
[0015] Preferably, the sterilization temperature in step (1) is 116-124°C.
[0016] Preferably, the sterilization time in step (1) is 18 to 24 minutes.
[0017] Preferably, the pH regulator in step (2) is sodium hydroxide.
[0018] The invention also provides application of the Mycoplasma gallisepticum culture medium in preparing Mycoplasma gallisepticum vaccine.
[0019] Preferably, the preparation method of the Mycoplasma gallisepticum vaccine is: inoculating the Mycoplasma gallisepticum seed liquid into the culture medium for cultivation, and harvesting when the pH of the culture medium drops from 7.6 to 6.4.
[0020] Preferably, the inoculation ratio of the Mycoplasma gallisepticum seed solution is 8-12% (V:V).
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The amino acids used in the present invention are all non-polar amino acids, which can effectively shorten the delayed growth period of Mycoplasma galli, so that it can be expanded and propagated as soon as possible. The present invention uses trehalose and glutathione together, which also has the effect of shortening the delayed period. This is because trehalose and glutathione can protect cells from oxidative stress and help form a favorable redox environment inside and outside the cells, which is conducive to the rapid passage of Mycoplasma galli through the delayed period.
[0023] The culture medium provided by the present invention can create a suitable nutritional condition for Mycoplasma gallisepticum, which is more conducive to the growth of Mycoplasma gallisepticum, and can also provide a full range of amino acids and trace elements for the growth of Mycoplasma gallisepticum, which can promote the metabolic process of Mycoplasma gallisepticum, significantly reduce the proportion of serum added, shorten the time of subculture, and improve the separation rate.
[0024] The culture medium provided by the present invention is easy to obtain and inexpensive, and can also meet the various nutrients required for the growth of Mycoplasma gallisepticum, which is conducive to the rapid growth of Mycoplasma gallisepticum. The titer of the semi-finished vaccine prepared by the method of the present invention is as high as 5.5×10 15 CCU / mL, and no concentration is required. Inactivated vaccines can be prepared directly or after dilution, which simplifies the production process and reduces production costs. DETAILED DESCRIPTION
[0025] The invention provides a Mycoplasma gallisepticum culture medium, which comprises the following components per liter of the culture medium: 15-20 g of yeast extract, 4-6 g of egg yolk phospholipids, 2-3 g of L-cysteine, 1.2-1.8 g of L-arginine hydrochloride, 1-2 g of L-phenylalanine, 1-2 g of L-alanine, 1-2 g of L-lysine, 0.2-0.6 g of methionine, 1-2 g of L-tryptophan, 1-2 g of L-proline, 2-4 g of zinc sulfate, 2-4 g of mannitol, 2-3 g of trehalose, 2-4 g of glutathione, 4-6 g of malt extract, 2-3 g of peptone, 5-7 mL of fetal bovine serum, 4-6 g of galactose, 0.2-0.4 g of potassium dihydrogen phosphate, and 2.2-2.8 g of sodium pyruvate;
[0026] Preferably, the mixture comprises 16-19 g yeast extract, 5 g egg yolk phospholipids, 3 g L-cysteine, 1.3-1.7 g L-arginine hydrochloride, 2 g L-phenylalanine, 2 g L-alanine, 2 g L-lysine, 0.3-0.5 g methionine, 2 g L-tryptophan, 2 g L-proline, 3 g zinc sulfate, 3 g mannitol, 3 g trehalose, 3 g glutathione, 5 g malt extract, 3 g peptone, 6 mL fetal bovine serum, 5 g galactose, 0.3 g potassium dihydrogen phosphate, and 2.3-2.7 g sodium pyruvate;
[0027] More preferably, 17-18 g yeast extract, 5 g egg yolk phospholipids, 3 g L-cysteine, 1.4-1.6 g L-arginine hydrochloride, 2 g L-phenylalanine, 2 g L-alanine, 2 g L-lysine, 0.4 g methionine, 2 g L-tryptophan, 2 g L-proline, 3 g zinc sulfate, 3 g mannitol, 3 g trehalose, 3 g glutathione, 5 g malt extract, 3 g peptone, 6 mL fetal bovine serum, 5 g galactose, 0.3 g potassium dihydrogen phosphate, and 2.4-2.6 g sodium pyruvate;
[0028] More preferably, it is 18 g yeast extract, 5 g egg yolk phospholipids, 3 g L-cysteine, 1.5 g L-arginine hydrochloride, 2 g L-phenylalanine, 2 g L-alanine, 2 g L-lysine, 0.4 g methionine, 2 g L-tryptophan, 2 g L-proline, 3 g zinc sulfate, 3 g mannitol, 3 g trehalose, 3 g glutathione, 5 g malt extract, 3 g peptone, 6 mL fetal bovine serum, 5 g galactose, 0.3 g potassium dihydrogen phosphate, and 2.5 g sodium pyruvate.
[0029] In the present invention, the pH value of the culture medium is 7.5-7.7, preferably 7.6.
[0030] In the present invention, the solvent of the culture medium is water.
[0031] The present invention also provides a method for preparing the Mycoplasma gallisepticum culture medium, comprising the following steps:
[0032] (1) mixing the components except fetal bovine serum with water and sterilizing to obtain material 1;
[0033] (2) After mixing the material 1 with fetal bovine serum, the pH is adjusted.
[0034] In the present invention, the sterilization temperature in step (1) is 116-124°C; preferably 117-123°C; more preferably 118-122°C; and more preferably 121°C.
[0035] In the present invention, the sterilization time in step (1) is 18 to 24 minutes, preferably 19 to 23 minutes, more preferably 20 to 22 minutes, and more preferably 21 minutes.
[0036] In the present invention, the pH regulator in step (2) is sodium hydroxide.
[0037] The invention also provides application of the Mycoplasma gallisepticum culture medium in preparing Mycoplasma gallisepticum vaccine.
[0038] In the present invention, the preparation method of the Mycoplasma gallisepticum vaccine is as follows: inoculating Mycoplasma gallisepticum seed liquid into the culture medium for cultivation, and harvesting the culture medium when the pH value drops from 7.6 to 6.4.
[0039] In the present invention, the inoculation ratio of the Mycoplasma gallisepticum seed solution is 8-12% (V:V); preferably 9-11% (V:V); and more preferably 10% (V:V).
[0040] In the present invention, the Mycoplasma gallisepticum seed liquid (CR strain) is derived from Ruipu Biopharmaceutical Co., Ltd.
[0041] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0042] Example 1
[0043] The invention discloses a Mycoplasma gallisepticum culture medium, which takes water as a solvent and comprises the following components per liter of the culture medium: 15 g of yeast extract, 4 g of egg yolk phospholipids, 2 g of L-cysteine, 1.2 g of L-arginine hydrochloride, 1 g of L-phenylalanine, 1 g of L-alanine, 1 g of L-lysine, 0.2 g of methionine, 1 g of L-tryptophan, 1 g of L-proline, 2 g of zinc sulfate, 2 g of mannitol, 2 g of trehalose, 4 g of glutathione, 4 g of malt extract, 2 g of peptone, 5 mL of fetal bovine serum, 4 g of galactose, 0.2 g of potassium dihydrogen phosphate and 2.2 g of sodium pyruvate.
[0044] The preparation method of the Mycoplasma gallisepticum culture medium comprises the following steps:
[0045] (1) mixing the components except fetal bovine serum with water, sterilizing at 116° C. for 18 min, and obtaining material 1;
[0046] (2) After mixing the material 1 with fetal bovine serum, the pH value was adjusted to 7.5 using sodium hydroxide.
[0047] Example 2
[0048] The invention discloses a Mycoplasma gallisepticum culture medium, which takes water as a solvent and comprises the following components per liter of the culture medium: 20g of yeast extract, 6g of egg yolk phospholipid, 3g of L-cysteine, 1.8g of L-arginine hydrochloride, 2g of L-phenylalanine, 2g of L-alanine, 2g of L-lysine, 0.6g of methionine, 2g of L-tryptophan, 1-2g of L-proline, 4g of zinc sulfate, 4g of mannitol, 3g of trehalose, 2g of glutathione, 6g of malt extract, 3g of peptone, 7mL of fetal bovine serum, 6g of galactose, 0.4g of potassium dihydrogen phosphate and 2.8g of sodium pyruvate.
[0049] The preparation method of the Mycoplasma gallisepticum culture medium comprises the following steps:
[0050] (1) mixing the components except fetal bovine serum with water, sterilizing at 124° C. for 24 min, and obtaining material 1;
[0051] (2) After mixing the material 1 with fetal bovine serum, the pH value was adjusted to 7.7 using sodium hydroxide.
[0052] Example 3
[0053] The invention discloses a Mycoplasma gallisepticum culture medium, which takes water as a solvent and comprises the following components per liter of the culture medium: 18g of yeast extract, 5g of egg yolk phospholipids, 3g of L-cysteine, 1.5g of L-arginine hydrochloride, 2g of L-phenylalanine, 2g of L-alanine, 2g of L-lysine, 0.4g of methionine, 2g of L-tryptophan, 2g of L-proline, 3g of zinc sulfate, 3g of mannitol, 3g of trehalose, 3g of glutathione, 5g of malt extract, 3g of peptone, 6mL of fetal bovine serum, 5g of galactose, 0.3g of potassium dihydrogen phosphate and 2.5g of sodium pyruvate.
[0054] The preparation method of the Mycoplasma gallisepticum culture medium comprises the following steps:
[0055] (1) Mixing the components except fetal bovine serum with water, sterilizing at 121° C. for 21 min, and obtaining material 1;
[0056] (2) After mixing the material 1 with fetal bovine serum, the pH value was adjusted to 7.6 using sodium hydroxide.
[0057] Example 4
[0058] A method for preparing a chicken mycoplasma vaccine comprises the following steps: inoculating a Mycoplasma gallisepticum seed solution (CR strain) at 8% (V:V) into the culture medium obtained in Example 1 and culturing at 37°C, and harvesting the culture medium when the culture medium turns yellow and the pH drops from 7.6 to 6.4.
[0059] Example 5
[0060] A method for preparing a chicken mycoplasma vaccine comprises the following steps: inoculating a 12% (V:V) mycoplasma gallisepticum seed solution (CR strain) into the culture medium obtained in Example 2 and culturing at 39°C, and harvesting the culture medium when the culture medium turns yellow and the pH drops from 7.6 to 6.4.
[0061] Example 6
[0062] A method for preparing a chicken mycoplasma vaccine comprises the following steps: inoculating a 10% (V:V) mycoplasma gallisepticum seed solution (CR strain) into the culture medium obtained in Example 3 and culturing at 37°C, and harvesting the culture medium when the culture medium turns yellow and the pH drops from 7.6 to 6.4.
[0063] Experimental Example 1
[0064] The titer and passage time of the product were measured. The specific measurement method was as follows: 26 test tubes were taken from each sample in different groups, each tube was filled with 1.8 mL of culture medium (prepared by the method in Example 3), 0.2 mL of the culture sample whose viable titer needed to be measured was added to the first test tube, mixed evenly on a micro-cyclotron oscillator, 0.2 mL was drawn and added to the second test tube, and a 10-fold serial dilution was performed to the 12th tube. No sample was added to the 13th test tube as a negative control.
[0065] All test tubes were placed in a 37°C constant temperature incubator for static culture, and observed once a day at a certain time period (around 10 o'clock) to observe the color change of the culture medium. The culture medium with added samples was compared with the negative control. The observation was continued for 7 days. The dilution of the test tube that finally showed color change was the CCU titer of the culture. This experiment was carried out 3 times in total, and different groups were passaged 3 times respectively. The data obtained from the investigation of each experimental group were averaged.
[0066] The product obtained by the method of Example 6 was used as the experimental group;
[0067] Control group 1: other methods were the same as those in Example 6, except that L-arginine hydrochloride, L-phenylalanine and L-alanine were not added to the culture medium in Example 3.
[0068] Control group 2: other methods were the same as those in Example 6, except that trehalose and glutathione were not added to the culture medium in Example 3.
[0069] The Mycoplasma gallisepticum CM2 culture medium was used as the prior art group, and its culture method was the same as that in Example 6.
[0070] Table 1 Titer questionnaire for different groups (unit: CCU / mL)
[0071] Group Generation 1 Generation 2 Generation 3 Experimental Group <![CDATA[1.6×10 14 ]]> <![CDATA[2.4×10 15 ]]> <![CDATA[5.5×10 15 ]]> Control group 1 <![CDATA[2.2×10 14 ]]> <![CDATA[6.2×10 14 ]]> <![CDATA[1.1×10 15 ]]> Control group 2 <![CDATA[4.1×10 12 ]]> <![CDATA[1.7×10 13 ]]> <![CDATA[7.8×10 13 <!-- 4 -->]]> Existing Technology Group <![CDATA[2.5×10 9 ]]> <![CDATA[1.6×10 10 ]]> <![CDATA[3.4×10 11 ]]>
[0072] Table 2 Questionnaire for passage time in different groups (unit: h)
[0073] Group Generation 1 Generation 2 Generation 3 Experimental Group 18.2 17.3 16.5 Control group 1 22.3 18.9 18.4 Control group 2 24.5 23.7 23.2 Existing Technology Group 25.1 24.4 23.4
[0074] From the data recorded in Table 1 and Table 2, it can be seen that the CCU titer of the three-generation culture test results of the Mycoplasma gallisepticum culture medium of the present invention is between 10 14 ~10 15 CCU / mL; the highest in traditional culture medium is only 3.4×10 11The shortest average culture time of the three generations of the Mycoplasma gallisepticum culture medium provided by the present invention is only 16.5 hours, while the average subculture time of the traditional culture medium is 23.4 hours, indicating that the Mycoplasma gallisepticum culture medium provided by the present invention has the characteristics of high viable bacteria titer and short subculture time.
[0075] From the data of control groups 1 and 2, it can be seen that only by adopting the complete formula of the present invention can the best technical effect be achieved. If some components are abandoned, the growth state of mycoplasma will be significantly affected, and then the titer and passage time of the vaccine will be significantly affected. In particular, trehalose and glutathione have the most significant effects on the growth state of mycoplasma.
[0076] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A Mycoplasma gallisepticum culture medium, characterized in that: Each liter of culture medium includes the following components: 15-20 g yeast extract, 4-6 g egg yolk phospholipids, 2-3 g L-cysteine, 1.2-1.8 g L-arginine hydrochloride, 1-2 g L-phenylalanine, 1-2 g L-alanine, 1-2 g L-lysine, 0.2-0.6 g methionine, 1-2 g L-tryptophan, 1-2 g L-proline, 2-4 g zinc sulfate, 2-4 g mannitol, 2-3 g trehalose, 2-4 g glutathione, 4-6 g malt extract, 2-3 g peptone, 5-7 mL fetal bovine serum, 4-6 g galactose, 0.2-0.4 g potassium dihydrogen phosphate, and 2.2-2.8 g sodium pyruvate.
2. The Mycoplasma gallisepticum culture medium according to claim 1, characterized in that The pH value of the culture medium is 7.5-7.
7.
3. The Mycoplasma gallisepticum culture medium according to claim 1, characterized in that The solvent of the culture medium is water.
4. The method for preparing the Mycoplasma gallisepticum culture medium according to any one of claims 1 to 3, characterized in that: The steps include: (1) mixing the components except fetal bovine serum with water and sterilizing to obtain material 1; (2) After mixing the material 1 with fetal bovine serum, the pH is adjusted.
5. The preparation method according to claim 4, characterized in that: The sterilization temperature in step (1) is 116-124°C.
6. The preparation method according to claim 4, characterized in that: The sterilization time in step (1) is 18 to 24 minutes.
7. The preparation method according to claim 4, characterized in that: The pH regulator in step (2) is sodium hydroxide.
8. Use of the Mycoplasma gallisepticum culture medium according to any one of claims 1 to 3 in the preparation of Mycoplasma gallisepticum vaccine.
9. The use according to claim 8, characterized in that: The preparation method of the Mycoplasma gallisepticum vaccine comprises: inoculating Mycoplasma gallisepticum seed liquid into the culture medium according to any one of claims 1 to 3 for cultivation, and harvesting the culture medium when the pH value thereof decreases from 7.6 to 6.
4.
10. The use according to claim 9, characterized in that: The inoculation ratio of the Mycoplasma gallisepticum seed liquid is 8-12% (V:V).
Citation Information
Patent Citations
Fluid culture medium and method for isolated-culturing mycoplasma gallisepticum using same
CN109913396A
Mycoplasma gallisepticum culture medium and preparation method thereof
CN112342158A
Mycoplasma synoviae culture medium and preparation method thereof
CN112410248A
